Pfizer, FDA

Pfizer’s colorectal cancer combo therapy gains accelerated approval from FDA
The accelerated approval is part of the FDA’s Project FrontRunner, aimed at advancing cancer drug development.
FDA approves new use for Pfizer’s Braftovi combo
US pharma giant Pfizer on Friday revealed that the US Food and Drug Administration (FDA) has approved its Braftovi (encorafenib) in combination with cetuximab and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation,
Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of metastatic colorectal cancer
Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of metastatic colorectal cancer: New York Monday, December 23, 2024, 10:00 Hrs [IST] Pfizer Inc anno
Pfizer gets FDA accelerated approval for Braftovi
Pfizer (PFE) has received FDA accelerated approval for its drug Braftovi in combination with other therapies for the treatment of colorectal cancer with a BRAF gene mutation.
FDA Grants Accelerated Approval To Pfizer's BRAFTOVI Combination For Metastatic Colorectal Cancer
Pfizer Inc. (PFE) said that the U.S. Food and Drug Administration has approved BRAFTOVI (encorafenib) in combination with cetuximab
Pfizer Gains FDA Approval for Colorectal-Cancer Treatment
Pfizer said Friday that the Food and Drug Administration approved its treatment for patients with metastatic colorectal cancer.
Pfizer's 2025 'Boring' Outlook Had A Nice Surprise That Was Overlooked
Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.
Pfizer announces FDA approval of Braftovi combination
Pfizer (PFE) announced that the Food and Drug Administration has approved Braftovi in combination with cetuximab and mFOLFOX6 for the ...
Yahoo Finance3d
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
NEW YORK, December 20, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI ® (encorafenib) in combination with ...